News | July 11, 2012

Study Shows Safety of Ultrasound Contrast Agent

Study evaluated more than 1,000 patients with wide-ranging characteristics, including pre-existing cardiopulmonary conditions and critical illness

Study Shows Safety of Ultrasound Contrast Agent

July 11, 2012 — Lantheus Medical Imaging Inc., a developer, manufacturer and distributor of diagnostic imaging agents, announced the publication of results from the CaRES (Contrast Echocardiography Registry for Safety Surveillance) multicenter safety registry for its ultrasound imaging agent Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The CaRES study found that Definity was well-tolerated in patients of different types undergoing clinically-indicated Definity-enhanced echocardiography in a broad range of typical clinical settings. The results were published in the July 2012 issue of the Journal of the American Society of Echocardiography (Weiss et al, 2012)

The prospective, open-label, nonrandomized registry study was designed to assess the risk of adverse clinical events occurring within 30 minutes of Definity administration in a routine clinical setting. Among the 1,053 patients who completed the study, no deaths, life-threatening events, serious adverse events or serious anaphylactoid (allergic) reactions were reported during or after Definity administration. The overall adverse event (AE) rate was 10.8 percent, and drug-related AE rate was 3.5 percent. Of the AEs that occurred during or after Definity administration, a substantial majority 96.5 percent were mild to moderate in intensity.

The CaRES study complements another recently published study on the hemodynamic effects of Definity in patients with pulmonary hypertension. Published in the May 2012 issue of the Journal of the American Society of Echocardiography (Wei et al, 2012), this prospective study evaluated 32 patients, half of whom had elevated baseline pulmonary artery systolic pressures. The study found that Definity administration did not result in any clinically meaningful changes in systemic and pulmonary artery hemodynamic measurements among patients with either normal or elevated pulmonary artery pressure. In addition, no serious or fatal adverse events occurred. Overall, Definity demonstrated a positive safety profile and was well-tolerated.

Both the CaRES study and the pulmonary hypertension study were developed in conjunction with the U.S. Food and Drug Administration (FDA) in 2008 as part of a risk assessment program for perflutren-based ultrasound contrast agents such as Definity.  In October 2011, the FDA approved several revisions to the Definity prescribing information, including the removal of mandatory physiologic monitoring requirements for patients with pulmonary hypertension or unstable cardiopulmonary conditions.  Data from both the CaRES and pulmonary hypertension studies were included in the updated Definity labeling.

For more information: www.definityimaging.com

Related Content

Philips Lumify Earns U.S. Army Airworthiness Certification
News | Ultrasound Imaging | May 22, 2019
Philips announced that Philips Lumify, a point-of-care ultrasound device, has earned the U.S. Army Airworthiness...
Clarius Releases Clarius Live Ultrasound Telemedicine Solution
Technology | Ultrasound Imaging | May 15, 2019
Clarius Mobile Health released a telemedicine solution called Clarius Live. The simple-to-use feature allows any...
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
Hong Kong Polytechnic University Develops Palm-sized 3-D Scoliosis Ultrasound Imaging System
News | Ultrasound Imaging | May 03, 2019
The Hong Kong Polytechnic University (PolyU) announced the development of a palm-sized 3-D ultrasound imaging system...
New Guideline Published for Evaluation of Valvular Regurgitation After Catheter-based Valve Interventions
News | Cardiovascular Ultrasound | April 30, 2019
A new document compiled by four cardiac imaging professional societies provides a resource to guide clinicians in best...
Six Predictions on How the Ultrasound Systems Market Will Expand Through 2022
News | Ultrasound Imaging | April 26, 2019
With healthcare costs continuing to rise, affordable and accurate imaging and diagnosis achieved through ultrasound...
ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Ebit and DiA Imaging Analysis Partner on AI-based Cardiac Ultrasound Analysis
News | Cardiovascular Ultrasound | April 16, 2019
DiA Imaging Analysis has partnered with the Italian healthcare IT company Ebit (Esaote Group), to offer DiA’s LVivo...
360 Photos | 360 View Photos | April 12, 2019
This 360 degree view shows staff at the ...
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...